NCT04709458尚未招募1 期
A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 4
- 主要终点
- Incidence of adverse events according to NCI-CTCAE Version 5.0
研究概览
简要总结
This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).
The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way.
This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe. The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment in adult subjects with AML or MF.
The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution after transplant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For crAML: AML with ≥5% blasts (either by morphology or by multi-parameter flow cytometry [MFC]) in a marrow aspirate obtained within 21 days of enrollment in the trial, and following the administration of at least two prior courses of chemotherapy;
- •For MF: primary MF or MF that has progressed from a myeloproliferative disease. Dynamic International Prognostic Scoring System (DIPSS)-plus to be utilized to support the inclusion of MF subjects at screening;
- •Subject undergoing allogeneic stem cell transplantation on the decision of transplanting physician;
- •Signed informed consent of donor and recipient;
- •Subjects of ≥ 18 years of age (no upper age limit);
- •Donor agrees to donate bone marrow-derived or mobilized peripheral blood stem cells;
- •Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;
- •Adequate pulmonary function with Diffusing Capacity for Carbon Monoxide (DLCO) > 50;
- •Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception (e.g. sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills) from screening until 6 months after TBX-2400 transplantation;
- •Able to adhere to all trial treatments and procedures.
排除标准
- •Previous stem cell transplantation;
- •For MF: Blasts > 10% in a marrow aspirate obtained within 30 days of screening;
- •Renal function: serum creatinine > 1.5 x Upper Limit of Normal (ULN);
- •Hepatic function: impaired synthetic function as indicated by a serum fibrinogen below the normal limit. Aspartate transaminase/alanine transaminase (AST/ALT) > 3.0 x ULN. Bilirubin, > 1.5 x ULN;
- •Cardiac function: ejection fraction < 45% as determined by echocardiography;
- •Prior malignancy active within previous three years - except for locally curable cancers such as cutaneous basal or squamous cell cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, or carcinoma in situ of the prostate;
- •Positive pregnancy test or breastfeeding for women of childbearing age;
- •Serologic evidence of chronic Hepatitis B virus infection or Hepatitis C exposure;
- •Known history of positive test for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS);
- •Hypersensitivity to any trial medication (including the preparative regimen, TBX-2400 treatment and any prophylaxis or other medication planned);
- •Presence of a serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with trial participation or trial drug administration, impair the ability of the participant to receive protocol therapy, or interfere with interpretation of trial results.
结局指标
主要结局
Incidence of adverse events according to NCI-CTCAE Version 5.0
时间窗: Two years
Adverse events from subject reporting or other assessments
Transplant engraftment
时间窗: 1 year
Assessment of transplant engraftment will include absolute neutrophil count, untransfused platelet count and donor chimerism
次要结局
- Immunoglobulin (IgM) levels(Up to Day 360)
- T-cell Engraftment(Up to Day 360)
- Quality of life using the World Health Organisation Five Wellbeing Index(Up to day 360)
- Incidence of secondary graft failure(Two years)
- Immunoglobulin (IgA) levels(Up to Day 360)
- Disease-free survival(Two years)
- Transplant-Related Mortality (TRM)(100 Days)
- Immune reconstitution as measured by CD3+ cell count(Up to Day 360)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
1 期
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined ImmunodeficiencySevere Combined ImmunodeficiencyNCT02860559Taiga Biotechnologies, Inc.8
已完成
1 期
Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal TransplantType 2 DiabetesType 1 DiabetesNCT00788827Imperial College London7
终止
1 期
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1HGraft FailureNCT00048399Baylor College of Medicine40
进行中（未招募）
1 期
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)Sickle Cell DiseaseNCT01499888University of Illinois at Chicago45
已完成
1 期
Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted MyocardiumCoronary ArteriosclerosisCoronary AtherosclerosisCoronary DiseaseCoronary Artery DiseaseNCT00548613TCA Cellular Therapy20